SOLIGENIX INC (SNGX)

Company Profile

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. The company is headquartered in Princeton, New Jersey and currently employs 13 full-time employees. The firm is focused on developing products to treat rare diseases. The company operates through two segments: Specialized BioTherapeutics and Public Health Solutions. Specialized BioTherapeutics business segment is developing and focused on commercialization of HyBryte (a proposed proprietary name of SGX301 or synthetic hypericin), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). This segment also includes dusquetide (SGX942) for the treatment of inflammatory diseases. Public Health Solutions business segment includes active development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19.

Company Info

SOLIGENIX INC

Suite C-10, 29 Emmons Drive

Princeton NEW JERSEY 08540

P: 16095388200

CEO: Christopher J. Schaber

Employees: 13

Website: https://www.soligenix.com/